Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739651 | 0.84 | KMT2A (0.47) | MAPTTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL6741864 | 0.84 | ALDH1A1 (0.42) | MAPTTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL6740329 | 0.83 | KMT2A (0.46) | MAPTALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL6743861 | 0.83 | TSHR (0.39) | MAPTTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL6740326 | 0.82 | ALDH1A1 (0.37) | MAPTTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL6746130 | 0.79 | ALPL (0.42) | KMT2AHSD17B10ALPLALPGPLAA | |
| SCHEMBL6884677 | 0.79 | METAP1 (0.31) | — | |
| SCHEMBL6740970 | 0.79 | ALPL (0.43) | KMT2AHSD17B10ALPLALPGPLAA | |
| SCHEMBL6743539 | 0.78 | CCNB2 (0.47) | TSHRKMT2AGAAALOX15STAT1 | |
| SCHEMBL6743052 | 0.74 | ESR1 (0.49) | MAPTALDH1A1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1395594-A1 | NEW BENZYLAMINOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094832-A1 | NEW BENZYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | MAPT 4405/4885TSHR 2503/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.